[{"id":"b5925ff8-a414-4e5c-8129-fb6140d88f40","acronym":"PNOC028","url":"https://clinicaltrials.gov/study/NCT05887882","created_at":"2024-06-08T04:17:18.068Z","updated_at":"2025-02-25T17:38:54.746Z","phase":"Phase 1","brief_title":"Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors","source_id_and_acronym":"NCT05887882 - PNOC028","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-01-29"},{"id":"da3993b4-3224-43f3-abf3-1a2b44201eaf","acronym":"TINKS","url":"https://clinicaltrials.gov/study/NCT05634369","created_at":"2023-12-20T08:17:53.968Z","updated_at":"2024-07-02T16:34:37.915Z","phase":"Phase 1/2","brief_title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","source_id_and_acronym":"NCT05634369 - TINKS","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • dexamethasone • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-05"}]